top of page
Multiple Myeloma Clinical Trials - Netherlands
NCT05572515
NCT05552222
NCT02773030
NCT05572515
1/30
Multiple Myeloma Clinical Trials Currently Recruiting
2022 - NCT05572515
Phase 3: MajesTEC-9 - Teclistamab alone Versus Pomalidomide-Bort-Dex or Carfilzomib-dex
2022 - NCT05552222
Phase 3: Teclistamab-Daratumumab-Len (Tec-DR) Vs Dara-Len-dex (DRd) (MajesTEC-7) NDMM
2022 - NCT05455320
Phase 3 - (Talquetamab) Tal-DP Vs Tal-D Vs DPd - RRMM -Multiple Myeloma (MonumenTAL-3)
2022 - NCT05317416
Phase 3: Elranatamab Versus Lenalidomide in Patients With NDMM post ASCT - MagnetisMM-7
2022 - NCT05257083
Phase 3: EMN 28 - DVRd -> Cilta-Cel (CART) Vs DVRd -> Transplant ASCT- NDMM CARTITUDE-6
2022 - NCT05243797
Phase 3: EMN 30 - Tec + Len Vs Len Alone NDMM as Maint. Therapy Post ASCT (MajesTEC-4)
2021 - NCT05160584
A Study of Real-Life Current Standards of Care in Participants With RRMM (MoMMent)
2021 - NCT05083169
Phase 3 - Tec-Dara Vs DPd Vs DVd in Relapsed or Refractory Myeloma - MajesTEC-3
2021 - NCT05050097
Phase 1 - A Study of Talquetamab With Other Anticancer Therapies in Multiple Myeloma
2021 - NCT05028348
Phase 3: EMN 29 - Selinexor, Pom, Dex (SPd) Vs Elotuzumab, Pom, Dex in RRMM Myeloma
2021 - NCT05020236
Phase 3-MagnetisMM-5: Elranatamab (PF-06863135) Vs & Elranatamab/Dara VS Dara/Pom/Dex
2021 - NCT04975997
Phase 3: IberDd Versus DVd in Participants With Relapsed Refractory Myeloma - EXCALIBER
2021 - NCT04923893
Phase 3 - VRd followed by Cilta-cel Vs VRd f/b Rd - NDMM- (No ASCT planned) CARTITUDE-5
2021 - NCT04887259
Phase 1/2: Trial of LAVA-051 in Patients With Relapsed/Refractory CLL, MM, or AML
2021 - NCT04721002
Evaluate t(11;14) Status & BCL2 Expression in Adult Participants With MM (MEDICI)
2020 - NCT04634552
Phase 2 - A Study of Talquetamab in Participants With Refractory Multiple Myeloma
2020 - NCT04564703
EMN26 Phase 2: Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients
2020 - NCT04557098
Phase 2- Teclistamab, in Participants With Relapsed or Refractory Myeloma (MajesTEC-1)
2020 - NCT04458831
A Non-interventional, Multinational, Observational study With Isatuximab in RRMM
2020 - NCT04392037
Phase 2: Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone (ICON)
2019 - NCT04133636
Phase 2 - Study of JNJ-68284528, CAR-T Therapy Directed Against BCMA in MM -CARTITUDE-2
2019 - NCT04126200
Phase 1/2 - Belantamab Mafodotin as Monotherapy & With Anti-cancer Rx (RRMM) (DREAMM 5)
2019 - NCT04108195
Phase 1b - Subcutaneous Dara With Bispecific T Cell Redirection Antibodies - TRIMM-2
2019 - NCT03871829
Phase 2: Retreatment in Participants With Myeloma Who Have Been Previously Rx with Dara
2018 - NCT03673826
Phase 2: Carfilzomib, Lenalidomide and Dex Versus Lenalidomide and Dex High- Risk SMM
bottom of page